Outcome of Board Meeting

& INDO US A" BIO-TECH LIMITED Indo-US (AN ISO CERTIFIED COMPANY) Agiiieeds CIN LO1122GJ2004PLC043550 Date: 12 August, 2026 BSE Limited National Stock Exchange of India Limited Dept. of Corporate Services, Dept. of Corporate Compliances, Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1 Block-G, Dalal Street, Bandra Kurla Complex, Mumbai- 400 001 Bandra (E) Mumbai- 400 051 BSE Scrip Code - 541304 NSE Symbol: INDOUS Sub: Outcome of Board Meeting held on August 12, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Dear Sir, Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held on Wednesday, 12 August, 2026 at the registered office of the Company situated at 309, Shanti Mall, Satadhar Char Rasta, Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, 380061 have considered and approved the following items of business: 1. The Board approved unaudited financial results of the company for the quarter ended 30 June, 2026 along with limited review reports obtained from the Auditor of the Company. The Board Meeting commenced at 14.30 P.M. and concluded at 15:10 P.M. You are requested to kindly take the same on record. Thanking you, For, Indo us Bio Tech Limited DIMPY Digeallysanebdy DIVPY DIVANGERALIOSH. DIVYANGBHAI pate. 2026081 151357 JOSHI o530’ Ms. Dimpy Joshi Company Secretary & Compliance officer | DSIR RECOGNITION IN HOUSE RAD UNIT E-mail : indous_jagdish{@yanoo.cion + indo-us_agrisciencesg@hotrm Wob " www indousaiseods com 7i INDO US § BIO-TECH LIMITED Indo-US (AN 1SO CERTIFIED COMPANY) Agriseeds CIN LO1122GJ2004PLC043550 o T Us Blotech e oo ans e, Satachar CO hI aN r: HL a0 s1 t1 a2 O2 pG pJ .2 0 N0 a4 wP a( n C go T4 o3 w5 e5 r0 , Sola Road, Abmedabad, Gularat 380081 B¢ o |Particusars Statement of Standalone Unau Bdite d Financial Resuits for ut ah re iq eu ra r Et ne dr nded on_June 30, 2026 1 [Refvrome Opnerautioens June 30, 2026 March 31,2026 June 30, 2025 March 31,2026 2 | TO ot th ae lr I i nn cc oom me e 33 ,, 32 10 1 18 2 .. . 06 3 58 8 22 ,6 600 422 .14 65 27 33 ,, 00 77 706 ... 119 156 11,043 91 3 P|uErxcpehnassees :o-f stock in trade Production Expenses 52419 30837 71514 311691 [( PC rh oga rn eg sse i asn n n d Sv toe ckn it n To rof a r dF ei .in ieshsed Goods, Workin. 862.55 344093 88395 783404 ; [FEimnpalnocyee Geo Bsetnse fits Expense } 1,2 23e1 65 2. 899 946 (1,9 2460 3 67 0.. 915 3 798 6) ! 8 4 21 35 03 2, .. ,1 002 0 464 (2. 1292 5464 02. 38 212 3 23)| {| | 54 |[ EP xr co ef pi tt i( oL no as ls ) tb ee mf so .r e r‘ ie ox rc e Pp et ri io on da l ti et me sm s and tax 3, 302 006 738 ..6 3. 759 0°0 2, 233 369 r64 .. 85 8 26 0 2, 452 808 165 ... 915 929 9 11 , ,, 6 31 5 97 7 23 . 3 06 1 20 |P |r To afi xt a xf pt ee nr ee xceptional item before tax 307.70 237.82 481.99 1,392.- D Te of te alr re Td ax T Ea xx p eCnh E aax crp gse n ses! (Written back) ©3a .2 7r 57s 02 1135 8.81 7523 Ti46 .89 705 s N2a 8 |NetProfit/(Lfoors tsh)ep eriod/year 9 [Other comprehensive income (net of tax) 303.74 19797 47024 1,312.29 tBA o.. (((( ri1ii o)) ) Il iI tt tnn ac mm nsos dm tt e hh a oT att sa ww sx ii el n lbn d ao t ta ib eb gv oar a se sc til efa mis ses di f hti aoe wt ioo r bto eaf .rni et o fs is 00 .. 00 2)8 ] { 00. .2 09 7)] 0 0. .7 28 0)] 10 |Total Comprehensive Income - 0.06 ©21) ©.B 11 | |P sa hi ad r- e)u p equity share capital (face value of Rs.10 per 303.74 187.11 47045 1,312.87 |O -DEt BiPh alSe i t (y a( cex ec Vl au ldi un eg r fe Rv sa .l 1u 0a /t -i eon ar ce hs )e rve) 2,005.20 2,005.20 2,005.20 2 7, .0 20 45 8. .2 10 ~Adjusted 11.5511 00.5988 223355 66.5544 Notes *not annualised 1.51 0.98 235 6.54 |t (1 h) e T Ch oe m f pi an nan yc i ha al v r ee s eu xl pt rs ew se sr ee d r ae nv ui ne mw oe dd i b fiy e t dh ‘e o pA iu nd ii ot n C oo nm tm hi et st ee re e sa uln td s. a pproved by the Board of Directors at its meeting held on 12.08.2026 and the Statutory Auditors (g 4{ ) T;) hv e7h f%‘ ic gwo uem rrp esea n hny ao i v s i e nd b ve eea s el t ni on r rg eci o gn m rpo oln uae pi‘ n etm sa j nor p eP nr do jd ngu , uc It r es ce ag im ve men dt , d ui. re. i nS g ‘e te hd e pCu el rt i mi ov gat ui no dn e, r P y ar ro pc ie es ws .i ng & Trading. CMARTERED ACCOUNTANTS For and on behalf of Boargl of Dire tors | Vi h D Ajudiya) Piac Managing Director| DIN: 01745951| Regd, Office: VXSSTTHSH Y DSIRRECOGNSNIITTIOIN ON IN HOUSE R&D UNIT , Shanti Mall, Sattadhar Cross Road, Factory A ddre€ ss : s gopgp N:Vlflng Tower, Ahmedabad-380 061. x‘::rg:::i?amfigg.?r"%:-bengam' L"é&i"?‘ifié&ffiifiéw" Dist-Gandhinagar, Gujarat, E-mail : indousexim@gmail.com e Web : www.indousagriseeds.com BHAGAT & ASSOCIATES CHARTERED ACCOUNTANTS oB-1204, SHIoLP CORPORATE P T CAR. K. BHAGAT BODAKDEV, AHMEDABAD-380054 CA MANISH BHAGAT @({ Q) +9197252 57136, +91 98790 61500 = bhagatasso@gmail.com, CA SHIKHA BHAGAT CA SUNIL PATEL | N D I A rkmbhagat@gmail.com @ https:;//www.bhagatandassociates.org CA VAIBHAV SHINGALA INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND- AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED. LIMITED REVIEW REPORT The Board of Directors, Indo US Bio-Tech Limited, Ahmedabad, Gujarat 1. We have reviewed the accompanying standalone statement of unaudited financial results of Indo US Bio-Tech Limited (CIN: L01122GJ2004PLC043550) (the company) for the quarter ended 30th June 2026 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended (Listing Regulations). 2. This standalone statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34 -Interim Financial Reporting' prescribed under section 133 of the Companies Act. 2013 (the Act) read with relevant rules issued there under and other recognized accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review. 0 3. We conducted our review of the standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying standalone statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules made thereunder and other accounting principles generally accepted in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclos [Showing first 8,000 characters — download PDF for full document]